Lyrica CR (pregabalin) extended release tablets, 330 mg, 30-count bottles, Rx only, Distributed by Parke-Davis Division of Pfizer Inc., NY, NY 10017, NDC 0071-1029-01
Published October 6, 2021 · Recall initiated: August 23, 2021
Summary
FDA records drug Class II recall D-0851-2021, published October 6, 2021 and initiated August 23, 2021. Recalling firm: Viatris; Status: Terminated; Reported quantity: 9,515 bottles; Lot: Lot #: DN5396, EP9726, EK2417, Exp. Date August 2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Dissolution Specifications
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Viatris
- Distributor
- Nationwide within the United States
- Lot
- Lot #: DN5396, EP9726, EK2417, Exp. Date August 2022
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDANeutrogena Beach Defense water+sun protection sunscreen spray BROAD SPECTRUM SPF 60+, Avobenzone (3%),October 6, 2021
- FDADaytime Severe Cold & Flu Relief 8 Pre-Measured Vials 0.51 FL OZ (15 mL) Each 4.06 FL OZ (120 mL)October 6, 2021
- FDANeutrogena Beach Defense water+sun protection sunscreen spray BROAD SPECTRUM SPF 50, Avobenzone (3%),October 6, 2021
- FDACVS Health Daytime Severe Cold & Flu Relief Single-Use Vials Mixed Berry Flavor 8 Pre-Measured Vials 0.51 FLOctober 6, 2021
- FDANeutrogena Ultra Sheer body mist sunscreen BROAD SPECTRUM SPF 30, Avobenzone (3%), Homosalate (8%), OctisalateOctober 6, 2021
- FDACandesartan Cilexetil Tablets, USP 16 mg, 30 count bottles, Manufactured for: Mylan Pharmaceuticals Inc.,September 22, 2021
Questions about this recall
Was Lyrica CR (pregabalin) extended release tablets, 330 mg, 30-count bottles, Rx only, Distributed by Parke-Davis Division of Pfizer Inc., NY, NY 10017, NDC 0071-1029-01 recalled?
Yes. FDA published recall D-0851-2021 on October 6, 2021. Reported hazard: Failed Dissolution Specifications
What should I do if I have this product?
Voluntary: Firm initiated · Letter